Publicaciones en colaboración con investigadores/as de Hôpital Européen Georges-Pompidou (189)

2024

  1. Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study

    European Urology

  2. Early versus delayed coronary angiography in patients with out-of-hospital cardiac arrest and no ST-segment elevation: a systematic review and meta-analysis of randomized controlled trials

    Clinical Research in Cardiology, Vol. 113, Núm. 4, pp. 561-569

  3. IFSO Consensus on Definitions and Clinical Practice Guidelines for Obesity Management—an International Delphi Study

    Obesity Surgery, Vol. 34, Núm. 1, pp. 30-42

  4. Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1)

    British Journal of Cancer, Vol. 130, Núm. 3, pp. 434-441

  5. Secondary Prevention Therapies in Real-World Patients with Myocardial Infarction: Eligibility Based on Randomized Trials Supporting European and American Guidelines

    American Journal of Medicine, Vol. 137, Núm. 2, pp. 137-146.e10

2023

  1. Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis registry

    European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 9, Núm. 1, pp. 42-53

  2. Care of patients with ST-elevation myocardial infarction: an international analysis of quality indicators in the acute coronary syndrome STEMI Registry of the EURObservational Research Programme and ACVC and EAPCI Associations of the European Society of Cardiology in 11 462 patients

    European Heart Journal: Acute Cardiovascular Care, Vol. 12, Núm. 1, pp. 22-37

  3. Changes in Liver Lipidomic Profile in G2019S-LRRK2 Mouse Model of Parkinson’s Disease

    Cells, Vol. 12, Núm. 5

  4. Economic evaluation of restrictive vs. liberal transfusion strategy following acute myocardial infarction (REALITY): trial-based cost-effectiveness and cost-utility analyses

    European heart journal. Quality of care & clinical outcomes, Vol. 9, Núm. 2, pp. 194-202

  5. Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy

    Kidney International Reports, Vol. 8, Núm. 12, pp. 2754-2764

  6. Glomerular diseases in pregnancy: pragmatic recommendations for clinical management

    Kidney International, Vol. 103, Núm. 2, pp. 264-281

  7. HPV Molecular Genotyping as a Differential Diagnosis Tool in Cervical Cancer Metastasis

    Journal of Personalized Medicine, Vol. 13, Núm. 2

  8. Impact of standard modifiable cardiovascular risk factors on 2-year all-cause mortality: Insights from an international cohort of 23,489 patients with acute coronary syndrome

    American Heart Journal, Vol. 264, pp. 20-30

  9. Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe

    ESMO Open, Vol. 8, Núm. 5

  10. TRANSLACOL project: Nodal human papillomavirus tumoral DNA detection by ddPCR for survival prediction in early cervical cancer patients without pelvic lymph node invasion

    Journal of Clinical Virology, Vol. 161

  11. TransFAIR study: a European multicentre experimental comparison of EHR2EDC technology to the usual manual method for eCRF data collection

    BMJ health & care informatics, Vol. 30, Núm. 1

  12. Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma

    European Urology

2022

  1. Autophagy Alteration in ApoA-I Related Systemic Amyloidosis

    International Journal of Molecular Sciences, Vol. 23, Núm. 7

  2. Correction: An obesogenic feedforward loop involving PPARγ, acyl-CoA binding protein and GABA receptor (Cell Death & Disease, (2022), 13, 4, (356), 10.1038/s41419-022-04834-5)

    Cell Death and Disease

  3. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up

    European Heart Journal, Vol. 43, Núm. 11, pp. 1059-1103